Antibody Drug Conjugates: windows of opportunity
Drug Target Review
JULY 4, 2023
For instance, we can compare the data from the 2021 DESTINY gastric cancer trial using the ADC Trastuzumab Deruxtecan with data from a gastric cancer trial in 2004 using the small molecule Irinotecan. Petra holds a D.Phil in synthetic organic chemistry and am MBA from Imperial College London. 2022 [cited 2023 Feb 10];30(2):71.
145 
Let's personalize your content